LRF Mantle Cell Lymphoma Consortium and SAB members make important strides toward the treatment of Burkitt lymphoma

The Lymphoma Research Foundation (LRF) is pleased to announce the recent achievements of Dr. Sandeep Dave of Duke University Medical Center in Durham, North Carolina and a member of the LRF's Mantle Cell Consortium (MCLC)*, as well as study co-authors that include Dr. Chris Flowers and Dr. Leo Gordon, members of LRF's Scientific Advisory Board (SAB), in their work on Burkitt's lymphoma.

With their findings recently published in November's edition of the prestigious journal, Nature Genetics, this study represents a significant step in improving drug development for this form of lymphoma and has the potential to suppress cancer cell proliferation in other lymphomas as well as other cancers. As explained by the study's senior author, Dr. Dave, this is the "first broad genetic landscape mapped of a Burkitt Lymphoma tumor", involving the identification of 70 mutations, "including several that had not previously been associated with cancer and a new one that is unique to the disease."

Burkitt lymphoma is an aggressive B-cell form of non-Hodgkin's lymphoma (NHL) that occurs primarily in children and young adults. One of the main issues with Burkitt lymphoma is its similarity with diffuse large B-cell lymphoma (DLBCL) which can lead to misdiagnosis and incorrect treatments. By mapping the genetic landscape of Burkitt lymphoma, researchers were able to discover "newly identified gene mutation ID3" which appears in 34 percent of Burkitt cases but which was not apparent in diffuse large B-cell lymphomas. Dr. Dave and his colleagues have identified some important differences between the two diseases, which will affect treatment options and should ultimately impact patient care as research in this area continues.

For more information on this study, click on the following link:

*About the Mantle Cell Lymphoma Consortium (MCLC)

Established by LRF in January 2005, the MCLC is comprised of more than 100 laboratory and clinical scientists from North America and Europe who focus their research on MCL. The MCLC is designed to accelerate the understanding and treatment of MCL by bringing together these lead investigators, funding innovative studies and creating resources.

Updated: December 2012